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ABSTRACT
Background: There is growing evidence indicating that children are less affected
from COVID-19. Some authors speculate that childhood vaccinations may provide
some cross-protection against COVID-19. In this study, our aim was to compare the
circulating antibody titers for multiple childhood vaccine antigens, as an indicator
of the state of immune memory between patients with COVID-19 and healthy
controls, with a specific aim to identify the association between disease severity and
antibody titrations which may indicate a protective function related to vaccine or
disease induced memory.
Methods: This study is a case-control study including 53 patients with COVID-19
and 40 healthy volunteers. COVID-19 severity was divided into three groups:
asymptomatic, mild and severe. We measured the same set of antibody titers for
vaccine antigens, and a set of biochemical and infection markers, in both the case and
control groups.
Results: Rubella (p = 0.003), pneumococcus (p = 0.002), and Bordetella pertussis
(p < 0.0001) titers were found to be significantly lower in the case group than the
control group. There was a significant decline in pneumococcus titers with severity of
disease (p = 0.021) and a significant association with disease severity for Bordetella
pertussis titers (p = 0.014) among COVID patients. Levels of AST, procalcitonin,
ferritin and D-dimer significantly increased with the disease severity.
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Discussion: Our study supports the hypothesis that pre-existing immune memory,
as monitored using circulating antibodies, acquired from childhood vaccinations, or
past infections confer some protection against COVID-19. Randomized controlled
studies are needed to support a definitive conclusion.
Subjects Immunology, Infectious Diseases, Internal Medicine, Public Health
Keywords COVID-19, Cross-protection, Antibody titers, Pandemic
INTRODUCTION
The whole world is struggling to control the 2019 Coronavirus Disease (COVID-19), and
facing unacceptable mortality in the hundreds of thousands in many countries (Dong,
Du & Gardner, 2020). Worldwide development of specific vaccines is underway. Even
though some are being approved today, it will take many months for them to be produced
and distributed to all susceptible people across the world. This window without a clear
pathway to protecting those at-risk mandates scientists seek other effective measures to
mitigate the severity of disease and reduce the future death toll.
Given the available data indicating that children are generally less likely to be affected
by COVID-19, and that those between 6 and 10 years of age have shown significantly
lower mortality and less severe disease (Dong et al., 2020) leads one wonder if the
compulsory child vaccination programs practiced in many countries have a role in
mitigating COVID disease in that age group. Further, it poses the question, can one or
more of these vaccines act as a vehicle for preventing, or modulating, the severity of
COVID-19?
In Turkey, where this study was conducted, an expanded childhood immunization
program is being implemented by the Ministry of Health. According to the estimates by
the World Health Organization and UNICEF, the coverage of basic childhood vaccines,
such as Bacillus Calmette-Guerin (BCG), Tetanus-diphtheria-pertussis, Polio, Measles,
Rubella, Hepatitis B, Haemophilus influenzae B and Pneumococcal conjugate vaccines
currently range between 88% and 99% of children in the country (World Health
Organization & UNICEF, 2020).
Our group was the first to hypothesize that childhood vaccines provide some level of
cross-protection against COVID-19 (Gold, 2020; Okyay et al., 2020). Soon afterwards,
several other authors proposed similar hypotheses (Salman & Salem, 2020; Lyu et al.,
2020). We proposed that one or more childhood vaccines, or comparable antibodies from a
past infections, may indicate a network of immune memory that can be reactivated to
provide some type of cross-protection. It may be adaptive elements, such as the antibodies
themselves which recognize coronavirus to some level, or it may be the product of
bystander activation by weakly recognized antigens that initiate reactivation of memory
clones which produce cytokines to drive the process of “trained innate immunity” through
tissue level priming of the local response network.
The enhancement of innate immune function by priming activation, more focused response
and better regulation has been recognized for a number of vaccines (Netea et al., 2016).
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The primary goal, and major benefit of vaccines is to provide either circulating available
effector activity against a specific agent, or a pool of memory cells capable of being
activated to provide rapid and lasting protection. A side benefit of many vaccines,
particularly live agent vaccines, is the development of lasting trained innate immunity.
In many places in the world scientists are currently testing the BCG vaccine for its
ability to provide a level of protection against COVID-19. They postulated the role of the
BCG vaccine based on prior research that showed the ability of BCG to protect against
unrelated infections. Also, epidemiological studies have shown an increase in COVID-19
prevalence in areas with lower vaccine use (Miller et al., 2020).
Measles vaccine was also proposed as a possible mitigator of COVID-19 disease.
Similarities were noted in their cutaneous manifestations (Recalcati, 2020). Further, the
measles vaccine has been used as a vector for other coronavirus specific vaccines including
Severe Acute Respiratory Syndrome (SARS) and the Middle East Respiratory Syndrome
Coronavirus (MERS-CoV). These vaccines were able to induce multifunctional T cell
response in a mouse model (Bodmer et al., 2018).
Studies are needed to further test these hypotheses. We hypothesized that there might
be a relationship between the levels of circulating antibodies we can measure, that we
believe reflect the memory pools acquired following childhood vaccinations, or past
infections, and COVID-19 disease. Therefore, in this study, our purpose was to measure
antibody titers in patients with COVID-19, and a matched pool of healthy controls from
the same community. This was done with the specific aim of measuring the association
between disease severity and antibody titers as predictors of protection in COVID-19
disease development.
MATERIALS AND METHODS
This study, planned as a case-control study, was conducted at the Adana City Training and
Research Hospital, Internal Medicine and COVID Clinic. Written informed consent of
patients and volunteers were obtained, between April 1, 2020 and May 1, 2020. During the
study, 53 patients with COVID-19 without co-morbidity, over the age of 18, and 40
healthy volunteers were included in the study.
Study population
Patients who were diagnosed by their histories, physical examinations, imaging and
laboratory findings, and who agreed to enroll in the study, were included. Patients with
diabetes mellitus, thyroid disease, hyperlipidemia, kidney failure, heart disease,
hematological disease, lung disease, rheumatic disease, presence of malignancy, pregnancy
and those who did not agree to participate in the study were excluded. After all patients
and healthy volunteers were included in the study, a detailed history was taken, a physical
examination was performed, and the age and sex of participants were recorded. The case
group was divided into three subgroups according to the severity of the disease:
asymptomatic, mild and severe COVID-19 cases.
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Laboratory testing
Both oropharyngeal and nasopharyngeal swabs were collected for each patient. The swabs
were taken to the laboratory and processed using rapid extraction kits. The samples were
assessed using a Roche LightCycler Instrument (Device reference number: 05815916001,
Serial number: 11927; Roche, Basel, Switzerland). They were handled and processed in
accordance with cold chain storage conditions. In addition to routine blood tests for the
patients and healthy volunteers included in the study, antibody titers were assessed.
For antibody titers, 5 cc blood samples were taken from the patients, the serum part was
separated by centrifugation for 10 min at 2,000 Revolutions Per Minute and placed in
Eppendorf tubes and stored at −80 C degrees. The hs-Troponin levels of the patients and
healthy volunteers included in the study was measured with the UniCel DXI Analyzer
(Beckman Coulter, Brea, CA, USA). Sodium (Na), potassium (K), calcium (Ca), glucose,
alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen
(BUN), creatinine, procalcitonin, sedimentation rate, C reactive protein (CRP), fibrinogen,
troponin, ferritin, D-dimer and whole blood cell levels were measured using an automated
Aeroset chemistry analyzer (Abbott, Plymouth, MN, USA) with appropriate Abbott
commercial kits.
Pre-existing antibody titers
Pre-existing antibodies to be measured were determined based on the vaccines commonly
used in childhood. Serum levels of Measles Virus IgG, Rubella Virus IgG, Mumps Virus
IgG, Diphtheria IgG, Bordetella pertussis IgG, Tetanus IgG,Haemophilus influenzae B IgG,
were evaluated using Serion ELISA classic (InstitutVirion\Serion GmbH Friedrich-
Bergius-Ring 19 97076 Würzburg, Germany) brand commercial kit. Serum levels of
Varicella-Zoster Virus IgG and Pneumococcus IgG were analyzed using the Testline
(TestLine Clinical Diagnostics Krizikova 68612 Brno Czech Republic) brand kit. The titers
of antibodies were determined using purified antigens.
Levels of ≥200, ≥20, ≥100, ≥1, ≥0.35, ≥50, ≥0.50, ≥1.15, and ≥15 antibody units were
considered as positive for measles, rubella, mumps, pneumococcus, diphtheria, Bordetella
pertussis, tetanus, varicella and Haemophilus influenzae B, respectively.
Statistical analysis
Data were expressed as values, percentages and medians (minimum-maximum).
In dichotomous variables, the difference between case and control was tested using the
Pearson’s chi-square test. The difference between quantitative parameters between case
and control was evaluated using the Mann Whitney U test. Disease severity was divided
into three groups as asymptomatic, mild and severe. The difference of quantitative
parameters among these three groups was evaluated with the Kruskal Wallis test. Post-hoc
analysis of Kruskal Wallis test was performed using Dunn test for significant results and
false discovery rates were also presented as Benjamini–Hochberg Adjusted p values.
Spearman correlation analysis was used to determine whether there was a correlation
between antibody titers and other measurement-related biological or biochemical
parameters.
Sumbul et al. (2021), PeerJ, DOI 10.7717/peerj.10910 4/16
Ethical considerations
The study was performed according to the tenets of the Declaration of Helsinki for
research involving human subjects. The study was approved by the Ethics Committee of
Çukurova University with the date of May 8, 2020 and number 52/99. The study was also
approved by the Ministry of Health. Written consent was obtained from the participants
before starting the study.
RESULTS
The median age of the case group included in the study was 42 (min = 21, max = 87), and
the median age of the control group was 51.5 (min = 25, max = 78). The age distributions
of both groups were similar (p = 0.186). The gender distribution of the case and control
groups were also similar (p = 0.694), 52.5% of the case group, and 56.6% of the control
group were male.
When comparing the case and control groups in terms of certain biological or
biochemical parameters, it was found that median Na, Ca, troponin, ferritin levels and
lymphocyte and platelet counts were significantly lower in the COVID-19 group.
In contrast the median ALT, AST, procalcitonin, CRP, fibrinogen D-dimer levels and
Table 1 Comparison of clinical parameters between case and control groups.
Biological or biochemical parameters Case group (Median (min–max)) Control group (Median (min–max)) p
Sodium 138.00 (129.00–143.00) 140.00 (135.50–143.20) <0.0001
Potassium 4.29 (3.57–4.92) 4.37 (3.89–5.18) 0.179
Calcium 9.00 (8.30–11.90) 9.50 (8.50–11.50) 0.013
Glucose 101.00 (68.00–346.00) 102.00 (75.00–377.00) 0.497
ALT 21.00 (6.00–71.00) 17.10 (7.50–62.80) 0.007
AST 28.00 (15.00–86.00) 21.50 (12.50–76.60) <0.0001
Urea 28.00 (11.00–115.00) 32.80 (16.60–55.00) 0.072
Creatinin 0.75 (0.36–2.12) 0.76 (0.46–1.59) 0.776
Procalcitonin 0.05 (0.03–50.00) 0.03 (0.01–0.05) <0.0001
Sedimentation 36.50 (13.00–120.00) 6.50 (1.00–11.00) <0.0001
C reactive protein 13.30 (1.45–223.00) 0.40 (0.00–1.35) <0.0001
Fibrinogen 348.42 (115.00–900.00) 236.50 (178.00–344.00) <0.0001
Troponin 4.00 (1.00–176.00) 10.00 (2.00–13.00) 0.003
Ferritin 68.00 (10.00–2714.00) 239.00 (167.00–356.00) <0.0001
D-dimer 472.00 (136.00–6950.00) 319.00 (237.00–389.00) <0.0001
WBC 6.00 (3.20–12.80) 6.00 (3.50–9.10) 0.855
Neutrophile 4.00 (1.50–9.00) 3.25 (2.00–6.20) 0.091
Lymhocyte 1.50 (0.40–2.40) 2.10 (1.20–3.80) <0.0001
Monocyte 0.60 (0.20–1.60) 0.60 (0.30–1.00) 0.987
Eosinophil 0.20 (0.10–0.60) 0.20 (0.00–0.80) 0.261
Hemoglobin 13.50 (8.80–16.00) 13.55 (10.40–16.50) 0.416
Plateletes 205.00 (111.00–393.000) 243.00 (95.00–485.00) 0.014
Notes:
min: minimum; max: maximum.
The parameters that were statistically significant in the comparison of the groups were indicated with bold.
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sedimentation rate were significantly higher in the COVID-19 group (Table 1). It should
be noted that two female patients had troponin values over the 16 ng/l threshold. None of
the controls exceeded this threshold.
We evaluated the differences in the antibody titers to the common vaccine antigens
between the two groups. All of the participants, both in case and control groups, were
positive for measles titers. Of the case group, all but three patients (94.3%), and of the
control group all but two people (95.0%), were positive for rubella. All participants, except
for one person in control group, were positive for mumps. Of the case group 22 patients
(41.5%), and of the control group 30 people (75.0%), were positive for pneumococcus,
and the difference between cases and controls was significant (p = 0.001). Of the case
group 17 patients (32.1%), and of the control group 12 people (30.0%), were positive for
diphtheria. Of the case group 10 patients (18.9%), and of the control group 27 people
(67.5%), were positive for Bordetella pertussis, the difference between cases and controls
was significant (p < 0.0001). Of the case group, 38 patients (71.7%), and of the control
group 21 people (52.5%), were positive for tetanus. Of the case group 49 patients (92.5%),
and of the control group 35 people (87.5%), were positive for Varicella. Of the case group
48 patients (90.6%), and of the control group 35 people (87.5%), were positive for
Haemophilus influenzae B.
When antibody titers were compared between case and control groups, the Rubella,
pneumococcus and Bordetella pertussis titers were found significantly lower in the case
group than the control group (Table 2).
The case group was divided into three groups according to the severity of the disease:
asymptomatic, mild and severe COVID-19 cases. The antibody titers and certain biological
or biochemical parameters were compared in these severity groups. The distribution of
titers for pneumococcus and Bordetella pertussis were significantly different with the
severity of the disease. Pneumococcus titers decreased in a clear fashion as the disease
became more severe. However, the difference in Bordetella pertussis titers was not clearly
indicative of the severity of disease. Rather, the titer was quite low among those with mild
disease impacting the finding of significance (Table 3). The levels of AST, procalcitonin,
Table 2 Comparison of pre-existing antibody titers between case and control groups.
Antibody titers Case group (Median (min–max)) Control group (Median (min–max)) p
Measles Ig G titers 9,632.50 (263.60–453,221.00) 6,919.75 (201.60–38,133.00) 0.207
Rubella Ig G titers 95.10 (1.30–300.90) 159.30 (17.80–1,833.40) 0.003
Mumps Ig G titers 1,194.00 (291.40–9,445.30) 986.90 (62.20–4,177.30) 0.251
Pneumococcus Ig G titers 0.79 (0.16–9.53) 2.30 (0.08–10.03) 0.002
DiphtheriaIg G titers 0.23 (0.01–1.38) 0.19 (0.03–1.77) 0.895
B. PertussisIg G titers 20.50 (4.50–511.20) 78.35 (1.70–693.50) <0.0001
TetanusIg G titers 1.20 (0.00–9.70) 0.55 (0.00–24.30) 0.489
Varicella Ig G titers 2.95 (0.66–6.28) 2.92 (0.47–5.77) 0.813
H. influenza BIg G titers 68.40 (5.00–1,522.60) 51.55 (7.00–407.50) 0.055
Notes:
min: minimum; max: maximum.
The parameters that were statistically significant in the comparison of the groups were indicated with bold.
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Table 3 Comparison of pre-existing antibody titers in terms of disease severity.







Measles Ig G titers 3,996.90 (263.60–39,643.00) 10,577.00 (684.00–453,211.00) 6,762.60 (1,462.80–38,254.00) 0.314
Rubella Ig G titers 79.15 (29.50–300.90) 108.20 (1.30–217.50) 95.05 (29.00–202.20) 0.897
Mumps Ig G titers 960.80 (402.80–6,060.30) 1,252.30 (291.40–9,445.30) 1,213.40 (361.00–3493.80) 0.820
Pneumococcus Ig G
titers
2.01 (0.21–7.38) 0.50 (0.17–9.53) 0.45 (0.16–1.28) 0.021
DiphtheriaIg G titers 0.38 (0.03–1.22) 0.18 (0.02–1.38) 0.18 (0.01–0.97) 0.551
B. Pertussis Ig G titers 37.95 (12.90–85.30) 17.00 (4.50–511.20) 36.15 (12.80–66.70) 0.014
TetanusIg G titers 1.65 (0.00–5.40) 1.10 (0.00–9.70) 1.40 (0.00–6.30) 0.740
Varicella Ig G titers 3.84 (1.34–6.28) 2.92 (1.10–5.09) 2.57 (0.66–4.86) 0.237
H. influenza BIg G titers 62.25 (17.30–299.00) 70.30 (5.00–965.60) 53.50 (9.40–1,522.60) 0.993
Notes:
min: minimum; max: maximum.
The parameters that were statistically significant in the comparison of the groups were indicated with bold.










Sodium 138.00 (136.00–141.00) 138.00 (129.00–142.00) 137.50 (132.00–143.00) 0.593
Potassium 4.21 (3.87–4.61) 4.31 (3.57–4.79) 4.36 (3.64–4.92) 0.616
Calcium 8.90 (8.30–9.80) 9.10 (8.40–10.00) 9.05 (8.30–11.90) 0.420
Glucose 102.50 (79.00–221.00) 99.00 (68.00–346.00) 104.50 (96.00–153.00) 0.470
ALT 20.00 (11.00–38.00) 21.00 (6.00–65.00) 36.50 (16.00–71.00) 0.237
AST 24.00 (20.00–32.00) 25.00 (15.00–86.00) 44.00 (33.00–73.00) <0.0001
Urea 27.00 (16.00–43.00) 27.00 (12.00–115.00) 35.00 (11.00–44.00) 0.428
Creatinin 0.72 (0.40–1.10) 0.74 (0.36–2.12) 0.78 (0.62–1.05) 0.579
Procalcitonin 0.05 (0.03–0.10) 0.05 (0.03–2.00) 12.00 (2.00–50.00) <0.0001
Sedimentation 29.00 (19.00–65.00) 38.50 (13.00–120.00) 79.00 (23.00–111.00) 0.117
C reactive protein 4.94 (1.49–58.40) 14.10 (1.45–195.00) 77.70 (2.50–223.00) 0.068
Fibrinogen 316.66 (199.60–378.89) 358.66 (167.28–694.00) 507.66 (115.00–900.00) 0.388
Troponin 3.00 (2.00–8.00) 4.00 (1.00–176.00) 6.50 (2.00–22.00) 0.245
Ferritin 29.35 (10.00–111.60) 104.30 (16.30–1,420.10) 365.00 (33.20–2,714.00) 0.022
D-dimer 338.50 (136.00–1,740.00) 440.00 (160.00–6,650.00) 1,134.00 (472.00–3,760.00) 0.017
WBC 5.65 (3.20–7.30) 6.10 (3.20–10.40) 6.80 (3.30–12.80) 0.333
Neutrophile 3.30 (1.50–5.10) 3.90 (1.70–8.70) 4.55 (2.10–9.00) 0.354
Lymhocyte 1.40 (0.80–2.00) 1.60 (0.40–2.30) 1.10 (0.90–2.40) 0.561
Monocyte 0.60 (0.50–0.80) 0.60 (0.30–1.00) 0.50 (0.30–1.60) 0.887
Eosinophil 0.30 (0.10–0.60) 0.20 (0.10–0.60) 0.15 (0.10–0.30) 0.330
Hemoglobin 13.30 (11.00–15.80) 13.60 (10.20–16.00) 13.00 (8.80–15.50) 0.771
Plateletes 183.50 (135.00–313.00) 213.00 (127.00–393.00) 198.00 (111.00–380.00) 0.566
Notes:
min: minimum; max: maximum.
The parameters that were statistically significant in the comparison of the groups were indicated with bold.
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ferritin and D-dimer appeared to increase with disease severity (Table 4). Post-hoc analysis
for results found significant after the comparison of the aforementioned three groups and
false discovery rates were also presented in Tables 5 and 6.
We observed significant correlations between the antibody titers and biological or
biochemical parameters in the COVID-19 group. The mumps titers showed a positive
correlation with lymphocyte count (Rho = 0.375, p = 0.006). The rubella titers showed a
negative correlation with the level of Ca (Rho = −0.353, p = 0.015). The pneumococcal
titers showed a negative correlation with the level of Ca (Rho = −0.296, p = 0.043).
The Bordetella pertussis titers showed a negative correlation with the sedimentation rate
(Rho = −0.498, p = 0.001) and with the CRP levels (Rho = −0.389, p = 0.010). The tetanus
titers showed a negative correlation with the level of D-dimer (Rho = −0.312, p = 0.023).
The varicella titers showed a negative correlation with the level of ALT (Rho = −0.384,
p = 0.005), the level of AST (Rho = −0.405, p = 0.003), procalcitonin (Rho = −0.319,
p = 0.048), the sedimentation rate (Rho = −0.404, p = 0.008) and the level of CRP
(Rho = −0.378, p = 0.012). TheH. influenzae B titers showed a positive correlation with the
level of Na (Rho = 0.402, p = 0.003).
DISCUSSION
In this study, we compared a set of randomly chosen healthy controls with a cohort of
COVID-19 patients being seen at the same institution and representing the same community.
We compared these populations with respect to a number of standard biochemical markers
Table 5 Post-hoc analysis of significant results observed in biochemical parameters when comparing disease severity groups.
Biochemical parameters Asymptomatic cases-Mild cases (1–2) Asymptomatic cases-Severe cases
(1–3)
Mild cases-Severe cases (2–3) KWc
pa FDRBH
b pa FDRBH p
a FDRBH p
AST 0.145 0.145 0.0001 0.0003 0.001 0.0015 <0.0001
Procalcitonin 0.743 0.743 0.001 0.0015 0.0001 0.0003 <0.0001
Ferritin 0.010 0.03 0.023 0.00345 0.598 0.598 0.022
D-dimer 0.341 0.341 0.006 0.018 0.015 0.0225 0.017
Notes:
a p value obtained with Dunn Test.
b Benjamini–Hochberg Adjusted p value.
c Kruskall Wallis test.
The parameters that were statistically significant were indicated with bold.
Table 6 Post-hoc analysis of significant results observed in antibody titers when comparing disease severity groups.
Antibody titers Asymptomatic cases-Mild cases (1–2) Asymptomatic cases-Severe cases (1–3) Mild cases-Severe cases (2–3) KWc
pa FDRBH
b pa FDRBH p
a FDRBH p
Pneumococcus Ig G titers 0.017 0.025 0.011 0.033 0.374 0.374 0.021
B. Pertussis Ig G titers 0.006 0.018 0.459 0.459 0.109 0.163 0.014
Notes:
a p value obtained with Dunn Test.
b Benjamini–Hochberg Adjusted p value.
c Kruskall Wallis test.
The parameters that were statistically significant were indicated with bold.
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and a rather large set of antibody titers representing common childhood vaccines, or
the disease they are designed to provide protection against. This was done to attempt to
establish some correlational information that would aid the diagnostic efficacy and
prognostic accuracy for COVID-19. We also investigated whether circulating antibodies
acquired due to childhood vaccinations, or past infections, appear to be related to a
protective effect that is involved in mitigating the severity of the disease.
We found that median sodium and calcium levels were lower in the COVID-19 group
than the controls. In a meta-analysis of disease biochemistry, it was reported that
COVID-19 patients have lower than normal sodium levels. Further, it was speculated that
low body sodium may have resulted in the overexpression of ACE-2. This would increase
the binding efficacy of SARS CoV-2 to cells and result in higher disease susceptibility
(Luo, Li & Dai, 2020). Di Filippo et al. (2020) found that hypocalcemia is highly prevalent
in COVID-19 patients. We believe that the assessment of sodium and calcium levels may
be of some assistance in diagnosis of COVID-19.
Median troponin levels were found lower in the COVID-19 case group in this study.
Yet we observed a progressive increase in troponin from asymptomatic to severe cases of
COVID-19. This was not, however, statistically significant. Also, two female COVID-19
patients (3.7% of all patients) had troponin over the 16 ng/l threshold, while none exceeded
this level in control group. There is evidence in the literature that SARS-CoV-2 may
cause myocardial injury in some patients (Li et al., 2020; Long et al., 2020). Huang et al.
(2020) reported 12% of patients having elevated levels of troponin. Although we found a
lower frequency in our study thanHuang et al. (2020) our findings support the observation
of myocardial damage in some COVID-19 patients.
We found that median ferritin levels were lower in the COVID-19 group than the
controls. However severe COVID-19 patients had higher median ferritin levels than did
the mild or asymptomatic cases, or the controls (See Tables 1 and 4). Mehta et al.
(2020) reported high ferritin levels in severe COVID-19 patients and indicated that high
ferritin levels may be associated with fatal hypercytokinaemia and the subsequent
multiorgan failure. We concluded from previous work and the confirmation from our
study that high ferritin levels may be a predictor of poor prognosis in COVID-19.
Lymphocyte and platelet counts were significantly lower in the COVID-19 group.
Lymphopenia is a common finding in COVID-19. It has been reported to be associated
with severe disease (Terpos et al., 2020). We also observed the lowest median lymphocyte
count in severe COVID-19 patients. Xu, Zhou & Xu (2020) suggested that SARS CoV-2
may reduce platelet production, increase platelet destruction and increase platelet
consumption. This would cause thrombocytopenia in COVID-19 patients. Some authors
also speculated that thrombocytopenia is associated with severe COVID-19 disease
(Terpos et al., 2020; Lippi, Plebani & Henry, 2020). In our study, although we did not find a
relationship between disease severity and platelet count, our findings support that platelet
levels may be low in patients with COVID-19.
Median ALT, AST, procalcitonin, CRP, fibrinogen D-dimer levels and sedimentation
rate were significantly higher in the COVID-19 group than the control group. All of these
biological or biochemical markers had their lowest levels in asymptomatic patients and
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their highest levels in patients with severe disease. For AST, procalcitonin and D-dimer
levels a statistically significant change was observed with the increasing severity of disease.
Several authors have reported elevated liver aminotransferase levels in COVID-19 patients.
Moreover they found it was associated with disease severity (Guan et al., 2020; Wang
et al., 2020a, 2020b). These findings indicated that SARS-CoV-2 may infect the liver itself
and cause cellular damage. Procalcitonin, CRP and sedimentation rate are all inflammatory
markers which are expected to increase in infectious diseases (Aringer, 2020). Velavan &
Meyer (2020) in their review, reported studies that find increased procalcitonin and CRP
levels in severe COVID-19. Lapić, Rogić& Plebani (2020) reported sedimentation rate is also
associated with severe COVID-19. In a meta-analysis increased procalcitonin values were
reported to be associated with a 5-fold higher risk of severe COVID-19 (Lippi & Plebani,
2020). We concluded that the increase in procalcitonin particularly indicates that bacterial
co-infections are probably concurrent with severe COVID-19. Several studies have shown
an increase in fibrinogen and D-dimer levels in COVID-19 patients, similar to our
observation (Gao et al., 2020; Panigada et al., 2020; Spiezia et al., 2020). This suggests that
coagulopathy is frequent in COVID-19 when low platelet levels are also taken into
consideration. We also think that the aforementioned biological or biochemical markers
may have prognostic values in COVID-19.
Our main hypothesis was to test whether pre-existing antibody titers confer protection
against COVID-19. Rubella, pneumococcus and Bordetella pertussis titers were found to be
significantly lower in the COVID-19 group than the control group. The distribution of
titers of pneumococcus and Bordetella pertussis significantly differed according to the
severity of the disease. Pneumococcus titers linearly decreased with the severity of the
disease. Bordetella pertussis titers, however, were found to be higher in both asymptomatic
and severe cases of COVID-19 and much higher in the controls, but lower in mild cases
(Tables 2 and 3). Franklin et al. (2020) reported that SARS-CoV-2 spike glycoproteins
share structural similarities with the fusion proteins of both measles and mumps viruses
and they found 29% amino acid sequence homology between the macro domains of
SARS-CoV-2 and rubella; and concluded that measles, mumps, rubella (MMR)
vaccination could improve the outcome of COVID-19 infection. Similarly, Gold reported
that MMR vaccine appears to confers protection from COVID-19 in a study of the
vaccination coverage in different countries around the world and their incidence of
COVID-19 disease (Gold, 2020). Although we found a significant difference in COVID-19
and control groups in terms of rubella titers, we did not find a significant relationship in
the severity of COVID-19 disease based on rubella titer.
There is evidence of pneumococcus and Bordetella pertussis co-infection in COVID-19
patients (Kozak et al., 2020; Zhu et al., 2020). Zhu et al. (2020) reported that 59.5% of
COVID-19 patients were infected with pneumococcus. Further a study published in
September, 2020 reported a potential cross-reactivity between SARS-CoV-2 proteins and
the pneumococcal proteins (Root-Bernstein, 2020). This may explain the lower
pneumococcus titers in severe COVID-19 patients found in our study. We found no
relation with Bordetella pertussis titer levels and the severity of the disease. However, the
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rate of individuals with positive IgG was significantly lower in the COVID-19 group as
compared to the controls.
With our findings, we cannot definitively say that a certain type of antibody interacts
with SARS-CoV-2 and creates a neutralizing effect and cross protection. The antibody
levels found in our study only show traces of previous infections or active immunization by
vaccination. Our findings may be interpreted with the concept of trained immunity as an
alternative mechanism of protection. Trained immunity can be described as “an innate
immune memory program induced by certain infections or vaccinations” (Netea & Van
der Meer, 2017). Although a recent study has found a relationship between MMR
vaccination and COVID-19 severity using mumps titers as a proxy (Gold et al., 2020), it
was not possible to verify this with our study, since we used alternate methodology. Live
pertussis vaccine has been reported to provide non-specific immune responses in mice
models, however this effect waned after the vaccine was inactivated by heat (Cauchi &
Locht, 2018). In Turkey, inactive tetanus-diphtheria-pertussis vaccines are given
simultaneously. In our study, a significant difference was found with Pertussis antibody
titers-, but not with tetanus or diphtheria antibody titers—between the control group and
the COVID-19 group. Also, Bordetella pertussis titers were higher in asymptomatic and
severe cases as compared to mild cases, which indicates that Bordetella pertussis antibodies
did not directly affect disease severity. This suggests that the presumed protection could
possibly be due to a silent Pertussis infection, which may induce trained immunity.
We have also observed some significant correlations with antibody titers with certain
biological or biochemical markers. Mumps titers showed a positive correlation with
lymphocyte counts. Rubella and Pneumococcus titers showed a negative correlation with
calcium levels. Bordetella pertussis titers showed negative correlations with sedimentation
and CRP levels. Tetanus titers showed a negative correlation with D-dimer levels.
Varicella titers showed negative correlations with ALT, AST, procalcitonin, sedimentation
and CRP levels. H. influenzae B titers showed a positive correlation with sodium levels.
These findings demonstrate that multiple different vaccines or past infections may provide
some level of protection against COVID-19 either in the form of weakly cross-reactive
antibodies, or by providing weakly cross-reactive reactivation of the adaptive memory
system and production of cytokines that prime, arm and regulate tissue level innate
immunity which retards coronavirus replication and spread in the body with a salutary
effect on the development of more severe disease.
Our study has some limitations. The sample sizes of both case and control groups were
small. Recruitment of healthy controls was difficult and costly in the pandemic era.
Therefore, there was an imbalance in case and control numbers. The titrations of antibody
for some of the childhood vaccines commonly delivered (Hepatitis A, Hepatitis B and
BCG and polio) were not included in the study. Also, it should be noted that we did not
investigate the vaccination history of patients. Thus, the antibodies measured are likely to
be due to natural infection as well as vaccination. Nonetheless, to the best of our
knowledge, our study was the first to measure pre-existing antibody titers and compare
them with healthy individuals. In addition, titers of nine major childhood vaccines were
measured in our study.
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In conclusion, we presented the biological or biochemical markers that changed in
COVID-19 patients as compared to healthy controls. We discussed how these markers
change according to the severity of COVID-19 disease. We observed that rubella,
Bordetella pertussis and pneumococcus titers were lower in COVID-19 patients than in
controls. We observed significant correlations between some of the antibody titers and
biological or biochemical markers. Our findings support the hypothesis that circulating
antibodies indicate some level of protection against COVID-19 that is associated with the
memory pool generated by childhood vaccines (or the diseases that they are designed
to protect against). Prospective randomized controlled studies are recommended to reach a
definitive conclusion.
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